Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
GlaxoSmithKline plc
Type
Public limited company
Traded as LSE: GSK
NYSE: GSK
Industry Pharmaceutical
Biotechnology
Consumer goods
Predecessor Glaxo plc
Wellcome plc
Beecham Group plc
Kline & French
Beckman Companies
Smith plc
Founded 2000
Headquarters Brentford, London, United Kingdom
Key people
  • Sir Philip Hampton
    (Chairman)
  • Andrew Witty
    (CEO)
Products Pharmaceuticals, vaccines, oral healthcare products, nutritional products, over-the-counter medicines
Revenue £23.006 billion (2014)
Operating income
£3.597 billion (2014)
Net income
£2.831 billion (2014)
Number of employees
96,575 (2015)
Subsidiaries Stiefel Laboratories
Slogan "Do more, feel better, live longer"
Website www.gsk.com
Footnotes / references
Key people (Chairman)

GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, London. It was the world's sixth-largest pharmaceutical company in 2014, after Pfizer, Novartis, Sanofi, Hoffmann-La Roche and Merck. It was established in 2000 by a merger of Glaxo Wellcome (formed from Glaxo's 1995 acquisition of Burroughs Wellcome) and SmithKline Beecham (from the 1989 merger of the Beecham Group and the SmithKline Beckman Corporation).

Portals:

French, Richards and Company
(Acq 1891)

Smith, Kline and Company
(Founded 1830)

Recherche et Industrie Thérapeutiques
(Acq 1968)

Specialized Instruments Corp.
(Acq 1954)

Offner Electronics
(Acq 1961)

Allergan
(Acq 1982, Sold 1989)

International Clinical Laboratories
(Acq 1989)

Norcliff Thayer
(Acq 1986)

S. E. Massengill Company
(Acq 1971)

C.L. Bencard
(Acq 1953)

County Chemicals
(Acq 1929)

Glaxo
(Founded 1850)

Joseph Nathan
(Acq 1947)

Allen & Hanburys
(Founded 1715, Acq 1958)

Meyer Laboratories
(Acq 1978)

Affymax
(Acq 1995)

McDougall & Robertson Inc
(Acq 1959)

Burroughs Wellcome & Company
(Founded 1880)

Laura Lorenzetti (24 July 2014). "GlaxoSmithKline seeks approval on first-ever malaria vaccine". Fortune. 

Katie Thomas and Michael S. Schmidt, "Glaxo Agrees to Pay $3 Billion in Fraud Settlement", The New York Times, 2 July 2012.

David J. Ravenscraft, William F. Long. "Paths to Creating Value in Pharmaceutical Mergers," in Steven N. Kaplan (ed.), Mergers and Productivity, University of Chicago Press, 2000.

David Cyranoski (29 October 2008). "Pharmaceutical futures: Made in China?". Nature. 

"Research-based pharma pledges on neglected tropical diseases". The Pharma Letter. 31 January 2012. 

Jim Edwards, "Inside GSK's CASSPER Ghostwriting Program", CBS News, 21 August 2009.

Steven M. Haffner, et al, "Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus," Circulation, 106(6), 6 August 2002, pp. 679–684. PubMed doi:10.1161/01.CIR.0000025403.20953.23

Philip D. Home, et al, "Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol," Diabetologia, 48(9), September 2005, pp. 1726–1735. PubMed doi:10.1007/s00125-005-1869-1

Gardiner Harris, "A Face-Off on the Safety of a Drug for Diabetes", The New York Times, 22 February 2010.

"Grassley, Baucus Release Committee Report on Avandia", The United States Senate Committee on Finance, 20 February 2010.

Avandia. Prescribing information", Food and Drug Administration.

Steven E. Nissen, "The rise and fall of rosiglitazone," European Heart Journal, 31(7), April 2010, pp. 773–776. PubMed doi:10.1093/eurheartj/ehq016

"Readjudication of the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes Trial (RECORD)", Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, Food and Drug Administration, 5–6 June 2013.

"Company hid suicide link", BBC News, 29 January 2007; "Secrets of the Drug Trials," BBC Panorama, 29 January 2007.

Marcia Angell (15 January 2009). "Drug Companies & Doctors: A Story of Corruption". The New York Review of Books 56 (1). 

"We have Frank and Vernon to thank for Ribena", The Bristol Post, 17 September 2013.

Tony Jaques, "When an Icon Stumbles – The Ribena Issue Mismanaged, Corporate Communications: An International Journal, 13(4), 2008, pp. 394–406.

"GlaxoSmithKline executives face China bribery probe". BBC News. 11 July 2013. 

Rupert Neate, "GSK’s China crisis: chief executive Andrew Witty speaks - as it happened", The Guardian, 24 July 2013. Tom Philips (26 July 2013). "Chinese police allege Glaxo sales reps trained to offer sexual bribes". The Daily Telegraph. 

Investment goal date:
Dividends reinvested
GlaxoSmithKline plc GSK report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q4 2017
2018-02-05
--
--
Q3 2017
2017-10-25
0.8500
0.6600
Q2 2017
2017-07-26
0.7000
-0.0900
Q1 2017
2017-04-26
0.6300
0.5400
Q2 2016
2017-04-11
0.6900
-0.2500
Q4 2015
2016-02-03
0.5500
-0.3500
Q3 2015
2015-10-28
0.7000
0.1300
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
AMERIPRISE FINANCIAL INC
3713030
BANK OF AMERICA CORP /DE/
6849632
Bank of New York Mellon Corp
5914985
BRANDES INVESTMENT PARTNERS, LP
3363788
FEDERATED INVESTORS INC /PA/
3677654
Fisher Asset Management, LLC
11969866
FMR LLC
23635038
GOLDMAN SACHS GROUP INC
3338789
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC
7524627
MORGAN STANLEY
4078260
PRICE T ROWE ASSOCIATES INC /MD/
10678557
RENAISSANCE TECHNOLOGIES LLC
4402100
ROYAL BANK OF CANADA
8731884
STATE STREET CORP
10491299
WELLS FARGO & CO/MN
12440851
Major Shareholders
Name Relationship
Total Shares
Holding stocks